The answer is refreshingly simple: no
Modern science validates their ability to boost detox enzymes, support liver function, and improve resilience
Wang L, Qi JH, Shi JH, Chen XJ, Gao HW
On Monday, 24th November, Novo Nordisk published a press release, explaining that the Evoke and Evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimers disease. Although the researchers did report significant reductions in biomarkers associated with Alzheimers, there was no reduction in disease progression in either trial
Safety Profile and Side Effects This is one area where the data is reassuringly consistent
doi:10.1186/s12964-024-01620-y 191